2023-04-27 08:15:00 ET
CRISPR Therapeutics (NASDAQ: CRSP) has been a volatile stock over the past couple of years. Lately, the gene-editing company's shares have been trading for under $51 a share, but I believe they could go much higher, considering the company's long-term potential.
CRISPR is one of just a handful of clinical-stage biotech companies (like Editas Medicine , Intellia Therapeutics , Beam Therapeutics and Verve Therapeutics ) that use CRISPR editing to find new therapies. However, CRISPR's lead therapy may be the first to get approval from the Food and Drug Administration (FDA).
Here are five reasons why it's not too late to buy CRISPR stock.
For further details see:
Is It Too Late to Buy CRISPR Stock?